NAGE Niagen Bioscience, Inc.

8-K Current Report

Filed: February 26, 2026

Health Care

Medicinal Chemicals & Botanical Products

Niagen Bioscience, Inc. (NAGE) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events

AI Filing Analysis
8-K

Item 7.01 · Regulation FD Disclosure

• Niagen Bioscience (NAGE) divesting its analytical reference standards and services business unit
• Asset sale signals strategic pivot — likely narrowing focus to core bioscience/NAD+ related operations

+1 more insights

Item 8.01 · Other Events

• All-cash divestiture of analytical reference standards and services business to VHG Labs (LGC Group), closed Feb 24, 2026
• Deal aligns with stated strategy to exit non-core assets and concentrate on NAD+ science platform, IP, and commercial growth

+3 more insights

Other Niagen Bioscience, Inc. 8-K Filings

8-K Mar 19, 2026

8-K Mar 4, 2026

Get deeper insights on Niagen Bioscience, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.